| 研究課題/領域番号 |
20K17053
|
|---|
| 研究種目 |
若手研究
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
小区分53010:消化器内科学関連
|
|---|
| 研究機関 | 香川大学 |
|---|
研究代表者 |
W Kittikulsuth (Kittikulsuth Wararat) 香川大学, 医学部, 研究員 (60746220)
|
|---|
| 研究期間 (年度) |
2020-04-01 – 2023-03-31
|
| 研究課題ステータス |
中途終了 (2022年度)
|
| 配分額 *注記 |
4,160千円 (直接経費: 3,200千円、間接経費: 960千円)
2022年度: 1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
2021年度: 1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
2020年度: 1,560千円 (直接経費: 1,200千円、間接経費: 360千円)
|
|---|
| キーワード | VIP antagonist / colon cancer / macrophages / VIPR2 / VIP hybrid / immunotherapy / cancer / PD-1 / immune checkpoint |
|---|
| 研究開始時の研究の概要 |
We would like to discover 1)whether combined therapy of PD-1 and VIP antagonist reduces tumor growth and metastasis in CT26-tumor bearing mice, and 2)the mechanisms on how combined therapy affects immune cell subsets and activities in tumor microenvironment.
|
| 研究実績の概要 |
VIP hybrid, a VIP antagonist, enhanced M1-related genes and increased phagocytic ability in macrophage RAW264.7 cells incubated with conditioned medium from colon cancer CT26 cells. In immunodeficient SCID mice, VIP hybrid alone or in combination with anti-PD-1 antibody attenuated CT26 tumor growth compared with the control. Analysis of tumor-infiltrating leukocytes found that VIP hybrid increased M1/M2 ratios and macrophage phagocytosis of CT26 cells. Moreover, Vipr2 gene silencing or VPAC2 activation affected the polarization of RAW264.7 cells incubated with conditioned medium from colon cancer CT26 cells. We concluded that VIP hybrid enhanced macrophage functions, thereby reducing tumor growth.
|
